<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280081</url>
  </required_header>
  <id_info>
    <org_study_id>17492</org_study_id>
    <secondary_id>J2G-GH-JZJK</secondary_id>
    <nct_id>NCT04280081</nct_id>
  </id_info>
  <brief_title>A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation</brief_title>
  <acronym>LIBRETTO-321</acronym>
  <official_title>A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug selpercatinib is safe and effective in&#xD;
      participants in China with rearranged during transfection (RET) fusion-positive solid tumors,&#xD;
      medullary thyroid cancer (MTC) and other tumors with RET activation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 16, 2020</start_date>
  <completion_date type="Anticipated">November 20, 2025</completion_date>
  <primary_completion_date type="Actual">March 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) by Independent Review Committee</measure>
    <time_frame>Baseline through Disease Progression or Death (Estimated at up to 30 Months)</time_frame>
    <description>ORR: Percentage of Participants with CR or PR by IRC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) by IRC</measure>
    <time_frame>Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Estimated at up to 30 Months)</time_frame>
    <description>DoR by IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) by IRC</measure>
    <time_frame>Baseline to Date of CR or PR (Estimated at up to 30 Months)</time_frame>
    <description>TTR by IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR): Percentage of Participants Who Achieve CR, PR or Stable Disease (SD) With a Duration of At Least 16 or More Weeks</measure>
    <time_frame>Baseline through Disease Progression or Death Due to Any Cause (Estimated at up to 30 Months)</time_frame>
    <description>CBR: Percentage of Participants Who Achieve CR, PR or SD With a Duration of At Least 16 or More Weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) by IRC</measure>
    <time_frame>Baseline to Progressive Disease or Death from Any Cause (Estimated at up to 30 Months)</time_frame>
    <description>PFS by IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to Date of Death from Any Cause (Estimated at up to 60 Months)</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Selpercatinib</measure>
    <time_frame>Baseline through End of Study (Estimated at up to 60 Months)</time_frame>
    <description>PK: AUC of Selpercatinib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Medullary Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Selpercatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selpercatinib given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selpercatinib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Selpercatinib</arm_group_label>
    <other_name>LY3527723</other_name>
    <other_name>LOXO-292</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with a locally advanced or metastatic solid tumor.&#xD;
&#xD;
          -  Evidence of a RET gene alteration in tumor and/or blood.&#xD;
&#xD;
          -  Measurable or non-measurable disease as determined by Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST) v1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2, with&#xD;
             no sudden deterioration 2 weeks prior to the first dose of study treatment.&#xD;
&#xD;
          -  Archived tumor tissue sample available for cohort 1 and 2.&#xD;
&#xD;
          -  Cohorts 1 and 2: failed or intolerant to standard of care.&#xD;
&#xD;
          -  Cohorts 1-2: enrollment will be restricted to participants with evidence of a RET gene&#xD;
             alteration in tumor (i.e., not just blood). However, a positive germline DNA test for&#xD;
             a RET gene mutation as defined in the protocol is acceptable in the absence of tumor&#xD;
             tissue testing for participants with MTC.&#xD;
&#xD;
          -  Cohorts 1-2: at least one measurable lesion as defined by RECIST v1.1 and not&#xD;
             previously irradiated (unless progressive disease for the irradiated lesion[s] has&#xD;
             been radiographically documented).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cohorts 1-2, an additional validated oncogenic driver that could cause resistance to&#xD;
             selpercatinib treatment if known.&#xD;
&#xD;
          -  Prior treatment with a selective RET inhibitor(s) (including investigational selective&#xD;
             RET inhibitor(s), such as BLU-667, RXDX-105, etc).&#xD;
&#xD;
          -  Are currently enrolled in any other clinical study involving an investigational&#xD;
             product or any other type of medical research judged not to be scientifically or&#xD;
             medically compatible with this study.&#xD;
&#xD;
          -  Any unresolved toxicities from prior therapy greater than common terminology criteria&#xD;
             for adverse events (CTCAE) Grade 1 except where otherwise noted in this eligibility&#xD;
             criteria at the time of starting study treatment with the exception of alopecia and&#xD;
             Grade 2, prior platinum therapy-related neuropathy.&#xD;
&#xD;
          -  Symptomatic primary central nervous system (CNS) tumor, symptomatic CNS metastasis,&#xD;
             leptomeningeal carcinomatosis, or untreated spinal cord compression.&#xD;
&#xD;
          -  Clinically significant active cardiovascular disease or history of myocardial&#xD;
             infarction within 6 months prior to planned start of selpercatinib or prolongation of&#xD;
             the QT interval corrected for heart rate using Fridericia's formula (QTcF) &gt; 470&#xD;
             milliseconds.&#xD;
&#xD;
          -  History of Human Immunodeficiency Virus (known HIV 1/2 antibodies positive);&#xD;
             participants with unknown HIV status do not need to be tested.&#xD;
&#xD;
          -  History of active hepatitis B (known positive hepatitis B surface antigen [HbsAg] and&#xD;
             quantitative hepatitis B DNA greater than the upper limit of detection of the assay)&#xD;
             or C (known positive hepatitis C antibody and quantitative hepatitis C RNA greater&#xD;
             than the upper limit of detection of the assay); participants with unknown hepatitis&#xD;
             B/hepatitis C status do not need to be tested.&#xD;
&#xD;
          -  Active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing&#xD;
             intercurrent illness, such as hypertension or diabetes, despite optimal treatment.&#xD;
             Screening for chronic conditions is not required.&#xD;
&#xD;
          -  Clinically significant active malabsorption syndrome or other condition likely to&#xD;
             affect gastrointestinal absorption of the study drug.&#xD;
&#xD;
          -  Uncontrolled symptomatic hyperthyroidism or hypothyroidism&#xD;
&#xD;
          -  Uncontrolled symptomatic hypercalcemia or hypocalcemia.&#xD;
&#xD;
          -  Concurrent use of drugs known to prolong QTc.&#xD;
&#xD;
          -  Pregnancy or lactation. Breast-feeding should be interrupted when selpercatinib is&#xD;
             started; breast-feeding can be resumed 3 months after discontinuation of&#xD;
             selpercatinib.&#xD;
&#xD;
          -  Active second malignancy other than minor treatment of indolent cancers with prior&#xD;
             sponsor approval.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanfang Affiliated Hospital South Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiated Hospital Of Guangzhou Medical Collage</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangzhou</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Province Tumor Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai/China</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hang Zhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hosp of College of Med, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 15, 2021</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Targeted Therapy</keyword>
  <keyword>Medullary Thyroid Carcinoma</keyword>
  <keyword>Thyroid Cancer</keyword>
  <keyword>RET Alteration</keyword>
  <keyword>MTC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Brain Stem Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

